November 16th, 2016
Tackling blood diseases and immune disorders
Startup Magenta Therapeutics licenses technologies from Harvard, MGH, and Boston Children’s that could transform treatment
News All News
Press Contact: Kirsten Mabry | (617) 495-4157
Tag: Accelerator
October 14th, 2016
The knotty problem of bringing regenerative medicine to market
First annual Harvard FUSION symposium assembles leaders at the convergence of science and business
April 27th, 2016
Advancing ingenuity
Five research projects with commercial potential receive sustaining funding through Harvard’s Physical Sciences & Engineering Accelerator.
August 19th, 2015
Bridging the biomedical development gap
Twelve advanced research projects aimed at developing new therapies and diagnostics receive support in 2015-16 from Harvard’s Blavatnik Biomedical Accelerator.
March 4th, 2015
Harvard startup launches with $22M Series A financing to develop novel macrolide antibiotics
NEWTON, Mass.--(BUSINESS WIRE)--Macrolide Pharmaceuticals, a new company with groundbreaking technology to develop novel antibiotics, completed a Series A financing of $22 million led by Novartis Venture Fund, Gurnet Point Capital, Roche Ventures, and SROne. The financing follows a worldwide license agreement between Harvard's Office of Technology Development and the company, providing exclusive rights to the technology.